NCT04197414 Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA
| NCT ID | NCT04197414 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yonsei University |
| Condition | Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2019-12-06 |
| Primary Completion | 2029-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2019-12-06 with a primary completion date of 2029-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Urological malignancies such as prostate cancer and renal cell cancer in Korean population have been increased due to the aged population and the westernized lifestyles. With the advancement of sequencing technologies, use of genetic mutation profiles in cancer detection and progression has been increased. However, use of circulating tumor DNA in urological malignances have been limited and few studies have been reported. Therefore, we tried to evaluate the usefulness of circulating tumor DNA in detection and monitoring of urological malignancies in Korean population. This study aims to use circulating tumor DNA in plasma and urine for the diagnosis, disease progression monitoring and therapeutic response evaluation. This study plan includes building big databases for circulating tumor DNA of urological malignancies in Korean population and to develop optimized circulating tumor DNA platform.
Eligibility Criteria
Inclusion Criteria: * 1\. Patients diagnosed as urological malignances (prostate cancer, renal cell cancer, bladder cancer, and ureter cancer) * 2\. Patients who have undergone surgeries due to urological malignancies in Severance Hospital, Sinchon from 2019.12 and 2029.11 * 3\. Those who agree to give permission to use their human source information - 4. Those who agree with this study Exclusion Criteria: * 1\. Those who do not agree with this study * 2\. Vulnerable participants who are likely to be vulnerable to coercion or undue influence or lack decision-making
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04197414 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04197414 currently recruiting?
Yes, NCT04197414 is actively recruiting participants. Contact the research team at uroham@yuhs.ac for enrollment information.
Where is the NCT04197414 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT04197414 clinical trial?
NCT04197414 is sponsored by Yonsei University. The trial plans to enroll 3,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.